【摘要】 目的评价深红诺卡菌细胞壁骨架（Ｎ－ＣＷＳ，胞必佳）治疗中、晚期恶性肿瘤的效果。方法恶性淋巴瘤２８例（霍奇金淋巴瘤５例，非霍奇金淋巴瘤２３例），采用三角肌下缘皮下注射Ｎ－ＣＷＳ结合化疗，并与单用化疗１８例（对照组）进行比较。恶性胸腔积液１５例，采用抽去胸水后胸腔内注入Ｎ－ＣＷＳ。恶性黑素瘤７例，采用皮下注射Ｎ－ＣＷＳ。结果５０例中，完全缓解（ＣＲ）１１例（２２％），部分缓解（ＰＲ）２１例（４２％）；总有效率为６４％。恶性淋巴瘤中，ＣＲ９例，ＰＲ１１例，有效率为７１．４％，而对照组中ＣＲ４例，ＰＲ７例，两者无显著差异。但在Ⅲ、Ⅳ期患者中两者有效率分别为６６．７％（１２／１８）和２７．３％（３／１１），有显著差异。恶性胸腔积液中，ＣＲ２例，ＰＲ８例，有效率为６６．７％。恶性黑素瘤中，ＰＲ２例。约５０％患者经Ｎ－ＣＷＳ治疗后出现免疫指标不同程度的提高。不良反应有发热（２８％，１４／５０）、局部肿胀（５１．４％，１９／３７）、硬结（１６．２％，６／３７）和疼痛（４６．７％，７／１５），但患者均能耐受。结论Ｎ－ＣＷＳ是具有抗肿瘤的免疫治疗药。更多还原

【Abstract】 To evaluate the efficacy of Nocardia rubra cell wall skeleton (N-CWS) in advanced malignant tumors.METHODS 50 patients with advanced malignant tumors were treated by N-CWS from November1990 to September 1992. There were 34 males and 16 female with a mean age of 43. 6 years (21～73). TheN-CWS was injected subcutaneously at the lower edge of the deltoid muscle, and combined withchemotherapy. The control group was 18 cases of chemotherapy alone.RESULTS Of these patients, there were 11 complete remissions and 21 partial remissions,yieldingan overall response rate of 64% (32/50). Responses by major responses to chemotherapy plus N-CWS (9CR, 11 PR),while in the confrol group, 11 of 18(61. 1 %: 4 CR, 7 PR). There was no significant differencebetween the two groups, but when comparisons were made between stageⅢ and Ⅳ,there did exist a significant difference (P<0.05). In the cases of malignant effusion, the response rate was 66. 7 % (10/15, with2 CR and 8 PR), similar to anticancer drugs or BMR, but less expensive. 2 out of 7 cases of malignantmelanoma were responsive (28. 6%,0 CR, 2 PR). Approximately 50% of patients treated by N-CWS haselevation of immunological status. Adverse reactions included fever (28 %, 14/50), local swelling (51. 4%,19/37),nodular change(16. 2%, 6/37)and pain (46. 756, 7/15),but were all tolerable.CONCLUSIONS N-CWS is inlmunotllerapeutic drug with anticancer properties.更多还原